Annals of Surgical Oncology

, Volume 24, Issue 12, pp 3715–3724 | Cite as

Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis

  • Daisaku Yamada
  • Hidetoshi Eguchi
  • Yoshifumi Iwagami
  • Yosuke Mukai
  • Yasuji Hashimoto
  • Tadafumi Asaoka
  • Takehiro Noda
  • Koichi Kawamoto
  • Kunihito Gotoh
  • Shogo Kobayashi
  • Yutaka Takeda
  • Masahiro Tanemura
  • Masaki Mori
  • Yuichiro Doki
Pancreatic Tumors



Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm that spreads to surrounding tissue or distant sites. This study investigated distant metastases in PDAC patients with or without preoperative chemoradiation therapy (CRT), focusing on vitamin D levels and bone density.


This study included 146 patients with PDAC who underwent surgery from 2007 to 2014. Bone density was evaluated using computed tomography, and the preoperative vitamin D level was calculated by enzyme-linked immunosorbent assay (ELISA) for patients with available plasma (48 cases).


When the patients were divided into two groups according to the change in bone density, the group with decreased bone density had a shorter distant metastasis-free survival time (DMFS) after surgery than the other group (p < 0.05). Low vitamin D was a weak predictor of DMFS, but the difference was not significant (p = 0.08), perhaps because of the sample size. Multivariate analysis indicated three significant factors associated with distant metastasis: a decrease in bone density (hazard ratio [HR], 2.17; p = 0.04), normalization of the Dupan-2 value after surgery (hazard ratio [HR], 0.39; p = 0.02), and completion of adjuvant chemotherapy (HR, 0.29; p < 0.01). Univariate analysis showed that a low vitamin D concentration (<20 pg/ml) was a risk factor (p = 0.04) for bone density change. Multivariate analysis found that preoperative CRT was the only factor associated (±, OR, 5.8; p = 0.04) with bone density change, suggesting that preoperative CRT significantly decreases bone density in patients with insufficient vitamin D.


Patients treated with preoperative CRT tend to have impaired bone density, which is a predictor of distant metastasis. Thus, vitamin D supplementation may decrease distant metastasis.



We thank Dr. Paul Kretchmer and all other editors at San Francisco Edit for providing language assistance.


There are no conflicts of interest.

Supplementary material

10434_2017_6040_MOESM1_ESM.docx (87 kb)
Supplementary material 1 (DOCX 86 kb)


  1. 1.
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mikamori M, Yamada D, Eguchi H, et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci Rep. 2017;7:42339.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tomihara H, Yamada D, Eguchi H, et al. MiR-181b-5p, ETS1 and c-Met pathway exacerbates the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci. 2017;108(3):398-407.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: the past, the present, and the future. Ann Gastroenterol Surg. 2017;1:5–10.CrossRefGoogle Scholar
  6. 6.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  7. 7.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Asari S, Matsumoto I, Toyama H, et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 2016;46:583–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Mizuguchi T, Torigoe T, Satomi F, et al. Trials of vaccines for pancreatic ductal adenocarcinoma: is there any hope of an improved prognosis? Surg Today. 2016;46:139–48.CrossRefPubMedGoogle Scholar
  10. 10.
    Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80–93.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Eguchi H, Nagano H, Tanemura M, et al. Preoperative chemoradiotherapy, surgery, and adjuvant therapy for resectable pancreatic cancer. Hepatogastroenterology. 2013;60:904–11.PubMedGoogle Scholar
  12. 12.
    Eguchi H, Nagano H, Kobayashi S, et al. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemother Pharmacol. 2014;73:309–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Takeda Y, Nakamori S, Eguchi H, et al. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Jpn J Clin Oncol. 2014;44:1172–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Tomihara H, Eguchi H, Yamada D, et al. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today. 2017;47:218–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamada D, Eguchi H, Asaoka T, et al. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surg Today. 2017. doi: 10.1007/s00595-017-1522-x.Google Scholar
  16. 16.
    Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMedGoogle Scholar
  17. 17.
    Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Geng Y, Qi Q, Sun M, Chen H, Wang P, Chen Z. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol. 2015;41:1508–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Watanabe J, Otani S, Sakamoto T, et al. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Surg Today. 2016;46(11):1258-1267.CrossRefPubMedGoogle Scholar
  21. 21.
    Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008;12:1422–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Weishaupt D, Schweitzer ME, DiCuccio MN, Whitley PE. Relationships of cervical, thoracic, and lumbar bone mineral density by quantitative CT. J Comput Assist Tomogr. 2001;25:146–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Pickhardt PJ, Lee LJ, del Rio AM, et al. Simultaneous screening for osteoporosis at CT colonography: bone mineral density assessment using MDCT attenuation techniques compared with the DXA reference standard. J Bone Miner Res. 2011;26:2194–203.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Yamada D, Kobayashi S, Yamamoto H, et al. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol. 2012;19(Suppl 3):S355–64.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamada D, Kobayashi S, Wada H, et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49:1725–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015;61:1627–42.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2014;383:146–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Hwang JH, Song SH, Lee JK, Lee NW, Lee KW. Bone mineral density after concurrent chemoradiation in patients with uterine cervical cancer. Menopause. 2010;17:416–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Duffy MJ, Murray A, Synnott NC, O’Donovan N, Crown J. Vitamin D analogues: potential use in cancer treatment. Crit Rev Oncol Hematol. 2017;112:190–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: stroma and its current and emerging targeted therapies. Cancer Lett. 2017;391:38–49.CrossRefPubMedGoogle Scholar
  33. 33.
    Yeo D, Phillips P, Baldwin GS, He H, Nikfarjam M. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Int J Cancer. 2017;140:2101–11.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Daisaku Yamada
    • 1
  • Hidetoshi Eguchi
    • 1
  • Yoshifumi Iwagami
    • 1
  • Yosuke Mukai
    • 1
  • Yasuji Hashimoto
    • 1
    • 2
  • Tadafumi Asaoka
    • 1
  • Takehiro Noda
    • 1
  • Koichi Kawamoto
    • 1
  • Kunihito Gotoh
    • 1
  • Shogo Kobayashi
    • 1
  • Yutaka Takeda
    • 1
    • 3
  • Masahiro Tanemura
    • 1
    • 4
  • Masaki Mori
    • 1
  • Yuichiro Doki
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of MedicineOsaka UniversitySuitaJapan
  2. 2.Department of SurgeryYao Municipal HospitalYaoJapan
  3. 3.Department of SurgeryKansai Rosai HospitalAmagasakiJapan
  4. 4.Department of SurgeryOsaka Police HospitalOsakaJapan

Personalised recommendations